News & Announcements
-
Holding(s) in Company
/**/ RNS Number : 6147Z IQ-AI Limited 15 January 2024 TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares
-
IB Launching an Expanded Access Program for GaM
/**/ RNS Number : 1417Z IQ-AI Limited 10 January 2024 IQ-AI Ltd (“IQ-AI” or the “Company”) Imaging Biometrics Launching an Expanded Access Program for Oral GaM Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI, OTCBB: IQAIF), is launching an intermediate population cohort expanded access program (EAP) for oral
-
Imaging Biometrics granted FDA “Fast-Track”
/**/ RNS Number : 3492X IQ-AI Limited 19 December 2023 IQ-AI Ltd (“IQ-AI” or the “Company”) Imaging Biometrics granted FDA “Fast-Track” Dec 19, 2023 – Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted “Fast-Track”
-
IQ-AI Announces Positive Interim Phase 1 Results
/**/ RNS Number : 7354V IQ-AI Limited 05 December 2023 IQ-AI Ltd (“IQ-AI” or the “Company”) IQ-AI Announces Positive Interim Phase 1 Results On-going trial to study the safety of oral gallium maltolate in relapsed GBM patients · All three planned dose levels tested to date continue to exhibit favorable safety and tolerability ·
-
Holding(s) in Company
/**/ RNS Number : 0230U IQ-AI Limited 20 November 2023 TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to